Results 291 to 300 of about 1,543,966 (410)

Reply

Arthritis &Rheumatology, EarlyView.
Spencer I. Danto, Elena Peeva
wiley   +1 more source

Tofacitinib for the Treatment of Juvenile Idiopathic Arthritis: Patient‐Reported Outcomes in a Phase III, Randomized, Double‐Blind, Placebo‐Controlled Withdrawal Trial

Arthritis &Rheumatology, Accepted Article.
Objective Juvenile idiopathic arthritis (JIA) is associated with impaired overall health‐related quality of life (HRQoL). We evaluated the impact of tofacitinib on patient‐reported outcomes (PROs) in patients with JIA. Methods This was a post hoc analysis of a phase III, randomized, double‐blind, placebo‐controlled withdrawal trial (NCT02592434) in ...
Hermine I. Brunner, Ekaterina Alexeeva, Marcia Bandeira, Ruy Carrasco, Jeffrey Chaitow, Peter Chiraseveenuprapund, Tracy V. Ting, Muferet Erguven, Beth Gottlieb, Sheila Knupp Oliveira, Pooja N. Patel, Seza Ozen, Claudia Saad Magalhaes, Inmaculada Calvo Penadés, David Gruben, Rebecca Germino, Holly B. Posner, Lori Stockert, Alberto Martini, Daniel J. Lovell, Nicolino Ruperto, The Paediatric Rheumatology International Trials Organisation (PRINTO) and Pediatric Rheumatology Collaborative Study Group (PRCSG)   +21 more
wiley   +1 more source

The Sustained Effects of Bioactive Collagen Peptides on Skin Health: A Randomized, Double-Blind, Placebo-Controlled Clinical Study. [PDF]

J Cosmet Dermatol
Wang Y, Zhu W, Luo W, Ma Y, Zhou Y.
europepmc   +1 more source

Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence.

Cochrane Database of Systematic Reviews, 2008
R. Mattick, J. Kimber, C. Breen, M. Davoli   +3 more
semanticscholar   +1 more source

Identification of histone deacetylase inhibitor targeting type I interferon and B‐cell abnormalities in systemic lupus erythematosus

Arthritis &Rheumatology, Accepted Article.
Objective Systemic lupus erythematosus (SLE) is characterized by increased type I interferon (IFN‐I) and autoantibody production. This study aimed to identify drugs that can inhibit both IFN‐I and autoantibody production. Methods We identified an inhibitor of IFN‐I production from a chemical library.
Takehiro Hirayama, Hachiro Konaka, Yasuhiro Kato, Takayuki Shibahara, Chisato Nishizawa, Kohei Tsujimoto, JeongHoon Park, Eri Itotagawa, Tatsunori Jo, Masayuki Nishide, Sumiyuki Nishida, Yoshihito Shima, Masashi Narazaki, Wataru Aoki, Ken J Ishii, Hyota Takamatsu, Atsushi Kumanogoh   +16 more
wiley   +1 more source

Effects of Oveporexton, an Orexin Receptor 2-Selective Agonist, on Cognition in Narcolepsy Type 1: A Secondary Analysis of a Randomized Clinical Trial.

JAMA Neurol
Lammers GJ, Plazzi G, Mignot E, Pizza F, Dauvilliers Y, Barateau L, Maruff P, Scammell TE, Latzman RD, Naylor M, Olsson T, Stukalin E, Tanaka S, Volfson D, Khachadourian V, Harel BT.   +15 more
europepmc   +1 more source

Oral Lacticaseibacillus rhamnosus GG Exposure During Pregnancy and Effects on Maternal Inflammatory Response-A Blinded, Pilot Randomized, Placebo-Controlled Study. [PDF]

Am J Reprod Immunol
Nordqvist M, Hallingström M, Nerén A, Bullarbo M, Kuusela P, Barman M, Thulin P, Sengpiel V, Jacobsson B.   +8 more
europepmc   +1 more source

A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.

New England Journal of Medicine, 2006
R. Belfort, S. Harrison, K. A. Brown, Celia Darland, J. Finch, Jean Hardies, B. Balas, A. Gastaldelli, F. Tio, Joseph P Pulcini, R. Berria, Jennie Z. Ma, S. Dwivedi, R. Havranek, C. Fincke, R. DeFronzo, G. Bannayan, S. Schenker, K. Cusi   +18 more
semanticscholar   +1 more source

THE PLACEBO SHRINE [PDF]

Journal of Clinical Pharmacy and Therapeutics, 1991
openaire   +2 more sources

Trial of Amitriptyline, Topiramate, and Placebo for Pediatric Migraine

New England Journal of Medicine, 2017
S. Powers, C. Coffey, L. A. Chamberlin, D. Ecklund, Elizabeth A. Klingner, Jon W. Yankey, L. Korbee, L. Porter, A. Hershey   +8 more
semanticscholar   +1 more source